October was an especially rough month for the sickly sector.
November 14, 2023
As a result, most of the funds, which emphasize fledgling, developmental biopharma companies, are now in the red for the year at the same time the broader market is up by double digits. Keep in mind that most of the life sciences and biopharma funds
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.